HEALTHCARE · NSE/BSE: RAINBOW

Rainbow Childrens Medicare Limited Earnings Summary — Q4 FY2026

Sentiment: Positive
AI-generated summary
Generated 2026-07-05
Business Intelligence Report

Rainbow Children's Medicare Reports Moderate Revenue Growth with Margin Resilience Amid Geographic Expansion

Quarterly Business Intelligence

Q1 FY2027
Financials from Financial Intelligence · data as of 2026-06-30
Revenue
₹470 Cr
QoQ +2.2%YoY +33.2%
Net Profit
₹61 Cr
QoQ -21.4%YoY +13.2%
Operating Profit
₹135 Cr
QoQ -7.0%YoY +29.9%
Operating Margin
28.6%
QoQ -282 bpsYoY -71 bps

AI Quarterly Scorecard™

67
/ 100
Healthy
Revenue Momentum84
Profit Growth47
Margin Expansion62
Growth Consistency91
Operating Efficiency58
Financial Stability59

Computed deterministically from the last 10 reported quarters.

Quarterly Business Momentum

Revenue & Growth
  • Revenue has increased for 5 consecutive quarters.
  • Revenue of ₹470 Cr is 33.2% higher year-on-year.
  • Revenue has compounded at 15.3% annualised over the last 10 quarters.
  • Revenue is at its highest level in 10 quarters.
Profitability
  • Net profit of ₹61 Cr is 13.2% above the same quarter last year.
  • Profit growth is trailing revenue growth this quarter.
  • Net profit has compounded at 8.0% annualised across the period.
Margins
  • Operating margin stands at 28.6% in Q1 FY2027.
  • Operating margin compressed by 71 bps year-on-year.
  • Over the last two years operating margin has expanded by 27 bps.
  • PBT margin is 17.9%.
Operating Efficiency
  • Expenses grew 34.5% against revenue growth of 33.2%.
  • Operating profit of ₹135 Cr is 29.9% higher year-on-year.
  • Operating leverage has been under pressure recently.
Overall Momentum
  • 6 of the last 6 measured quarters delivered year-on-year revenue growth.
  • Overall quarterly business momentum scores 67/100 (Healthy) on the latest 10 quarters.
  • Business momentum remains positive heading into the next quarter.

Quarterly Financials

Last 10 Reported Quarters • All figures in ₹ Crore • Margins in %

MetricTrend
Latest
Q1 FY2027
Q4 FY2026Q3 FY2026Q2 FY2026Q1 FY2026Q4 FY2025Q3 FY2025Q2 FY2025Q1 FY2025Q4 FY2024
Revenue
Improving
470
460445445353370398417330341
Expenses
Improving
335
315298296249255264270236236
Operating Profit
Improving
135
14514714910411513414794106
Operating Margin
Stable
28.6%
31.5%33.0%33.5%29.4%31.0%33.8%35.2%28.4%30.9%
Other Income
Volatile
13
4118201513111213
Interest
Stable
21
212019181818181817
Depreciation
Improving
42
414036343435353432
Profit Before Tax
Improving
84
87981027177941055369
Tax
Volatile
21
92427182025261418
Net Profit
Improving
61
777375545669794051
Net Margin
Stable
12.9%
16.8%16.3%16.9%15.2%15.2%17.3%18.9%12.0%14.9%
Source: Financial Intelligence (Structured Quarterly Data)Latest Quarter: Q1 FY2027Figures in ₹ Crore • Margins in %Automatically updated from Financial Intelligence · 2026-06-30

Key Takeaways

  • Revenue grew 24.3% year-on-year to ₹460 crores, demonstrating sustained demand in the niche pediatric segment.
  • Net profit saw a significant 36.8% YoY jump, primarily aided by a sharp reduction in effective tax rate to 10% this quarter.
  • Operating Profit Margin remained healthy at 31%, although it softened compared to the 33% seen in the preceding two quarters.
  • Borrowings increased to ₹891 crores by year-end, reflecting capital-intensive expansion and bed capacity additions.
  • The company maintains a strong doctor-partnership model, which continues to drive high clinician retention and specialized care quality.
  • Expansion into NCR and other clusters is ongoing, with significant focus on the 'Rainbow' and 'Birthright' brands.
  • Cash flow from operations remains robust at ₹420 crores for the full year, supporting aggressive capex plans.

Management Guidance

Management remains focused on adding 1,000+ beds over the medium term. They intend to deepen penetration in established Hyderabad and Bengaluru clusters while expanding the hub-and-spoke model into new territories like NCR and other urban centers.

Sentiment Shift

Stable

While margins faced slight quarterly pressure, the strong year-on-year revenue and profit growth, combined with high operational consistency, reinforces the company's position as a high-quality compounder.

Expansionary
Disciplined
Specialized
Consistent

Outlook

The outlook remains healthy with a clear roadmap for capacity expansion and a focus on maintaining high ARPOB and occupancy through specialized pediatric quaternary care.

From the Annual Report (Key Quotes)

Strategy of involving senior clinicians as partners has led to high doctor retention, a critical success factor.

Clear roadmap for adding 1,000+ beds over the medium term without compromising on the quality of care.

The business has demonstrated exceptional compounding, with a 10-year sales CAGR of 22%.

Official Quarterly Documents

Earnings Press Release
Official quarterly earnings release published by the company.
Press Release not available.
Earnings Call Transcript
Management discussion and analyst Q&A.

This summary is AI-generated from Rainbow Childrens Medicare Limited's latest quarterly filing and earnings call. For informational purposes only — not investment advice.

← Back to Rainbow Childrens Medicare Limited AI analysis